Agilent to Acquire Resolution Bioscience

March 3, 2021

Cleary Gottlieb is serving as antitrust counsel to Agilent Technologies Inc. (Agilent), which announced on March 3, 2021, that it has entered into a definitive agreement to acquire Resolution Bioscience Inc. (Resolution Bioscience).

The acquisition complements and expands Agilent’s capabilities in next-generation sequencing (NGS)-based cancer diagnostics and provides the company with innovative technology to further serve the needs of the fast-growing precision medicine market. Under the terms of the agreement, Agilent will pay $550 million in cash at closing and up to an additional $145 million based on achieving future performance milestones.

Resolution Bioscience is a leader in the development and commercialization of NGS-based precision oncology solutions.